1. A method for the targeted delivery of a pharmaceutical composition of a kinase inhibitor into the respiratory tract of a patient in need of such treatment, comprising:! administering to the patient a therapeutically effective amount of a pharmaceutically acceptable composition suitable for direct delivery to the respiratory tract and comprising:! (a) from about 0.00001 to about 10% w / v kinase inhibiting agent selected from: 6,7-bis (3-hydroxyphenyl) -teridine-2,4-diamine or its pharmaceutically acceptable salts； and! (b) from about 0.00001 to about 10% w / v surfactant,! however, the introduction of the composition leads to the delivery of the drug mainly to the surface of the mucous membrane of the respiratory tract of the patient and provides a minimum concentration of an agent that inhibits kinase in the patient's plasma. ! 2. The method according to claim 1, in which the pharmaceutically acceptable composition also includes a water-based solvent. ! 3. The method according to claim 1, in which the concentration of the agent in the plasma of the patient (a) reaches less than about 10 ng / ml within about two hours after administration； or (b) less than about 2 ng / ml within about two hours after administration. ! 4. The method according to claim 1, in which (a) the surfactant is selected from one or more of the following substances: tyloxapol, poloxamer 188, poloxamer 407, tween 80, phosphatidylcholine, phosphatides or phosphatidylglycerols； or (b) the surfactant is tyloxapol. ! 5. A composition suitable for administration by inhalation or nasal, comprising:! a) the active substance of the formula I:! ! where! each of Z2 and Z4 is C, each of Z1, Z3, Z5 and Z6 is N； ! each X is NH2； ! each Y, independently,1. Способ направленной доставки фармацевтической композиции ингибитора киназы в дыхательные пути пациента, нуждающегося в таком лечении, включающий: ! введение пациенту терапевтически эффективного количества фармацевтически приемлемой композиции, пригодной
